Description

Cartalax is a defined synthetic tetrapeptide consisting of the amino-acid sequence Ala-Glu-Asp-Leu (AEDL). It is supplied in lyophilized form for controlled laboratory and analytical investigation where consistent peptide identity, defined sequence information, and structured experimental documentation are required.

Supplied exclusively for laboratory research, analytical testing, and scientific investigation, Cartalax 20mg may be utilized in appropriately controlled experimental environments involving peptide characterization, sequence-based analytical studies, comparative peptide investigations, molecular interaction research, cartilage-associated in vitro research models, chromatographic evaluation, analytical assay development, stability assessment, degradation analysis, and other non-clinical laboratory applications.

Cartalax is prepared and documented under controlled quality procedures intended to support material identification, batch consistency, traceability, and analytical transparency. Its defined four-amino-acid sequence provides researchers with a characterized material for peptide identity assessment, chromatographic comparison, sequence verification, and appropriately designed molecular research workflows. Batch-specific analytical documentation may be available to support material verification and laboratory recordkeeping.

Research Applications

Cartalax may be utilized in laboratory research activities including:

• Tetrapeptide identity and characterization studies
• Peptide sequence analysis
• Comparative peptide investigations
• Molecular interaction studies
• Cartilage-associated in vitro research models
• Chromatographic and analytical evaluation
• Analytical assay development
• Stability and degradation assessments
• Controlled in vitro laboratory research

Research applications may vary according to laboratory protocols, institutional requirements, analytical methods, experimental design, and individual study objectives.

Storage & Handling

To help maintain material integrity:

• Store lyophilized material at -20°C or as directed in the accompanying product documentation.
• Protect from excessive heat, moisture, and direct light.
• Following preparation for laboratory analysis, maintain storage conditions according to validated research protocols.
• Avoid unnecessary repeated freeze-thaw cycles.
• Handle using appropriate laboratory safety procedures and aseptic techniques where applicable.

Quality Assurance

Cartalax 20mg is supplied under established quality-control procedures designed to support laboratory consistency, material identification, traceability, and research transparency. Quality review may include chromatographic analysis, peptide identity assessment, sequence verification, batch verification, product traceability, and supporting analytical documentation. A Certificate of Analysis (COA) or related batch analytical documentation may be available for the applicable lot.

Additional Information

Research Use Disclaimer

FOR RESEARCH USE ONLY (RUO).

Cartalax 20mg is supplied exclusively for laboratory research, analytical testing, and scientific investigation purposes.

This product is not intended for human consumption, veterinary use, clinical applications, diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition.

This material is not represented as a drug, food, cosmetic, dietary supplement, or therapeutic product. By purchasing this material, the buyer acknowledges that it is intended solely for appropriately controlled research environments and must be handled in accordance with applicable laboratory procedures, institutional requirements, and laws.